DDInter1912 DDInter1657
Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases.
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.[L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant. Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2 lines of systemic therapy. The FDA approved Selinexor in June 2019. The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Valganciclovir {u} (Compound) resembles {v} (Compound) Penciclovir
Valganciclovir {u} (Compound) resembles {v} (Compound) Acyclovir
Valganciclovir {u} (Compound) binds {v} (Gene) SLC15A1
Valganciclovir {u} (Compound) is included by {v} (Pharmacologic Class) Nucleoside Analog
Valganciclovir {u} (Compound) causes {v} (Side Effect) Anorexia
Valganciclovir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Valganciclovir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acalabrutinib
Valganciclovir {u} may lead to a major life threatening interaction when taken with {v} Certolizumab pegol
Valganciclovir {u} may lead to a major life threatening interaction when taken with {v} Infliximab
Valganciclovir (Compound) resembles Penciclovir (Compound)
Valganciclovir (Compound) resembles Acyclovir (Compound)
Valganciclovir (Compound) binds SLC15A1 (Gene)
Valganciclovir (Compound) is included by Nucleoside Analog (Pharmacologic Class)
Valganciclovir (Compound) causes Anorexia (Side Effect)
Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene
Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Valganciclovir may lead to a major life threatening interaction when taken with Certolizumab pegol
Valganciclovir may lead to a major life threatening interaction when taken with Infliximab